Template:Infobox drug/testcases

Infobox drug/testcases
Legal status
Legal status	AU: S2 (Pharmacy medicine); BR: Class A1 (Narcotic drugs); CA: Schedule I; DE: Anlage I (Authorized scientific use only); UK: General sales list (GSL, OTC); US: ℞-only;

Infobox drug/testcases
Clinical data
Other names	synonyms
Biosimilars	rituximab-abbs, rituximab-pvvr, rituximab-arrx
AHFS/Drugs.com	Monograph

Infobox drug/testcases
Clinical data
Other names	synonyms
Biosimilars	rituximab-abbs, rituximab-pvvr, rituximab-arrx
AHFS/Drugs.com	Monograph

This is the template test cases page for the sandbox of Template:Infobox drug. Purge this page to update the examples.
If there are many examples of a complicated template, later ones may break due to limits in MediaWiki; see the HTML comment "NewPP limit report" in the rendered page.
You can also use Special:ExpandTemplates to examine the results of template uses.
You can test how this page looks in the different skins and parsers with these links:

__EXPECTUNUSEDTEMPLATE__

v t e Infobox drug development (Drugbox - talk central, overview, sandboxes, testcases) WT:PHARM
`/sandbox:` {{Drugbox}} · e {{title}} · e · src {{licence}} · e · src {{legal}} · e · src {{pregcat}} · e · src {{molarmass}} · e · src {{mab source}} · e · src {{localINNvar}} · e · src {{maint cat}} · e · src {{fmtATC}} · e · src /format · Infobox drug/sandbox (edit · t · history · diff · links · /test · Source · e · t · hist · links · /subpages · /doc · /doc edit) FDA-2023 {{Infobox drug/doc/FDA-2023}} · /testcases-FDA -- 2023 · /sandbox2 parameters Full parameter list (edit) · Type-conditional sections TPU cats:Category:Infobox drug tracking categories (24): Category:Pages using infobox drug with unknown parameters (7) · Parameter usage report cat:IBdrug templates · cat:Templates used in IBdrug testcases (m view): Template:Infobox drug/testcases -- General /testcases2 -- titles, licence, EMA /testcases3 -- pregcat, legal, licence, PLLR, ATC; Wikidata /testcases4 -- chem formula, mab /testcases5 -- identifiers, second id's /testcases6 -- all up /testcases7images -- images /testcases8 -- type, titles /testcases9 -- order variants, container_only /testcases10 -- pharmacokinetic, localINN (2017) has (data page) -- is a redirect /testcases11 -- hormone, gene therapy (2018), has (data page) /testcases-FDA -- FDA 2023 /testcases-warning -- warning box(es) RC recent changes Chem+Drugbox templates · Drugbox transclusions Module:TemplatePar bot Settings.css · Settings/sandbox · {{cascite}} chembox {{Chem/dev/nav}} · {{Chembox}} Infobox drug class/sandbox (edit · t · history · diff · links · /test · Source · e · t · hist · links · /subpages · /doc · /doc edit) `Purge`

biosimilars

eg Rituximab

Side by side comparison

References

^ "Truxima- rituximab-abbs injection, solution". DailyMed. Retrieved 26 March 2021.
^ "Ruxience- rituximab-pvvr injection, solution". DailyMed. Retrieved 26 March 2021.
^ "Riabni- rituximab-arrx injection, solution". DailyMed. Retrieved 26 March 2021.

Test Brazilian Legal Status

Side by side comparison

Infobox drug/testcases
Legal status
Legal status	AU: S2 (Pharmacy medicine) BR: Class A1 (Narcotic drugs) CA: Schedule I DE: Anlage I (Authorized scientific use only) UK: General sales list (GSL, OTC) US: ℞-only

Test 0 = blanks

Side by side comparison

Test 1

Purge

Side by side comparison

Infobox drug/testcases
INN: Linezolid
Clinical data


Pronunciation	/njuːˈmoʊniə/
Trade names	Linospan, Zyvox, Zyvoxam, Zyvoxid
Other names	Lenzomore
AHFS/Drugs.com	Monograph
MedlinePlus	a602004
License data	EU EMA: by INN US DailyMed: Linezolid US FDA: Linezolid
Pregnancy category	AU: C
Dependence liability	High
Addiction liability	Low
Routes of administration	Intravenous infusion, oral
ATC code	J01XX08 (WHO)
Pharmacokinetic data
Bioavailability	~100% (oral)
Protein binding	Low (31%)
Metabolism	Hepatic (50–70%, CYP not involved)
Metabolites	some stuff
Onset of action	1 hr
Elimination half-life	4.2–5.4 hours (shorter in children)
Duration of action	1 to 3 hr
Excretion	Nonrenal, renal, and fecal
Identifiers
IUPAC name (S)-N-({3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide
CAS Number	165800-03-3^Y
PubChem CID	441401
IUPHAR/BPS	1234
DrugBank	DB00601
UNII	ISQ9I6J12J
KEGG	D00947^Y
ChEMBL	ChEMBL126^Y
NIAID ChemDB	070944
PDB ligand	ZLD (PDBe, RCSB PDB)
Chemical and physical data
Formula	C₁₆H₂₀FN₃O₄
Molar mass	337.346 g/mol g·mol⁻¹
3D model (JSmol)	Interactive image
Density	1.40 g/cm³
Melting point	135 °C (275 °F)
Boiling point	140 °C (284 °F) (decomposes)
Solubility in water	3 mg/mL (20 °C)
SMILES O=C1O[C@@H](CNC(=O)C)CN1c3cc(F)c(N2CCOCC2)cc3
InChI InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1^Y Key:TYZROVQLWOKYKF-ZDUSSCGKSA-N^Y
^NY (what is this?) (verify)

Infobox drug/testcases
INN: Linezolid
Clinical data


Pronunciation	/njuːˈmoʊniə/
Trade names	Linospan, Zyvox, Zyvoxam, Zyvoxid
Other names	Lenzomore
AHFS/Drugs.com	Monograph
MedlinePlus	a602004
License data	EU EMA: by INN US DailyMed: Linezolid US FDA: Linezolid
Pregnancy category	AU: C
Dependence liability	High
Addiction liability	Low
Routes of administration	Intravenous infusion, oral
ATC code	J01XX08 (WHO)
Pharmacokinetic data
Bioavailability	~100% (oral)
Protein binding	Low (31%)
Metabolism	Hepatic (50–70%, CYP not involved)
Metabolites	some stuff
Onset of action	1 hr
Elimination half-life	4.2–5.4 hours (shorter in children)
Duration of action	1 to 3 hr
Excretion	Nonrenal, renal, and fecal
Identifiers
IUPAC name (S)-N-({3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide
CAS Number	165800-03-3^Y
PubChem CID	441401
IUPHAR/BPS	1234
DrugBank	DB00601
UNII	ISQ9I6J12J
KEGG	D00947^Y
ChEMBL	ChEMBL126^Y
NIAID ChemDB	070944
PDB ligand	ZLD (PDBe, RCSB PDB)
Chemical and physical data
Formula	C₁₆H₂₀FN₃O₄
Molar mass	337.346 g/mol g·mol⁻¹
3D model (JSmol)	Interactive image
Density	1.40 g/cm³
Melting point	135 °C (275 °F)
Boiling point	140 °C (284 °F) (decomposes)
Solubility in water	3 mg/mL (20 °C)
SMILES O=C1O[C@@H](CNC(=O)C)CN1c3cc(F)c(N2CCOCC2)cc3
InChI InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1^Y Key:TYZROVQLWOKYKF-ZDUSSCGKSA-N^Y
^NY (what is this?) (verify)

Purge

Test 2

Side by side comparison

Infobox drug/testcases
Clinical data

Pronunciation	/njuːˈmoʊniə/
Other names	3{[(4-cyclopentyl-1-piperazinyl)imino]methyl}rifamycin
AHFS/Drugs.com	Monograph
MedlinePlus	a602026
ATC code	J04AB05 (WHO)
Pharmacokinetic data
Bioavailability	increases when administered with food
Onset of action	1 hr
Identifiers
IUPAC name (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z,26E)-26-{[(4-cyclopentylpiperazin-1-yl)amino]methylidene}-2,15,17,29-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27-trioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^4,7.0^5,28]triaconta-1(28),2,4,9,19,21,25(29)-heptaen-13-yl acetate
CAS Number	61379-65-5
PubChem CID	5462354
DrugBank	APRD01217
ChemSpider	10482075^Y
UNII	XJM390A33U
KEGG	D00879^N
ChEBI	CHEBI:45304^N
ChEMBL	ChEMBL1660^N
NIAID ChemDB	007686
Chemical and physical data
Formula	C₄₇H₆₄N₄O₁₂
Molar mass	877.031 g/mol g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC(=O)O[C@H]3[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(\C)C(=O)Nc6c(/C=N/N1CCN(CC1)C2CCCC2)c(O)c5c4C(=O)[C@@](C)(O/C=C/[C@H](OC)[C@H]3C)Oc4c(C)c(O)c5c6O
InChI InChI=1S/C47H64N4O12/c1-24-13-12-14-25(2)46(59)49-37-32(23-48-51-20-18-50(19-21-51)31-15-10-11-16-31)41(56)34-35(42(37)57)40(55)29(6)44-36(34)45(58)47(8,63-44)61-22-17-33(60-9)26(3)43(62-30(7)52)28(5)39(54)27(4)38(24)53/h12-14,17,22-24,26-28,31,33,38-39,43,53-57H,10-11,15-16,18-21H2,1-9H3,(H,49,59)/b13-12+,22-17+,25-14-,48-23+/t24-,26+,27+,28+,33-,38-,39+,43+,47-/m0/s1^Y Commenting here^[1] Key:WDZCUPBHRAEYDL-GZAUEHORSA-N^Y
^NY (what is this?) (verify)

Infobox drug/testcases
Clinical data

Pronunciation	/njuːˈmoʊniə/
Other names	3{[(4-cyclopentyl-1-piperazinyl)imino]methyl}rifamycin
AHFS/Drugs.com	Monograph
MedlinePlus	a602026
ATC code	J04AB05 (WHO)
Pharmacokinetic data
Bioavailability	increases when administered with food
Onset of action	1 hr
Identifiers
IUPAC name (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z,26E)-26-{[(4-cyclopentylpiperazin-1-yl)amino]methylidene}-2,15,17,29-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27-trioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^4,7.0^5,28]triaconta-1(28),2,4,9,19,21,25(29)-heptaen-13-yl acetate
CAS Number	61379-65-5
PubChem CID	5462354
DrugBank	APRD01217
ChemSpider	10482075^Y
UNII	XJM390A33U
KEGG	D00879^N
ChEBI	CHEBI:45304^N
ChEMBL	ChEMBL1660^N
NIAID ChemDB	007686
Chemical and physical data
Formula	C₄₇H₆₄N₄O₁₂
Molar mass	877.031 g/mol g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC(=O)O[C@H]3[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(\C)C(=O)Nc6c(/C=N/N1CCN(CC1)C2CCCC2)c(O)c5c4C(=O)[C@@](C)(O/C=C/[C@H](OC)[C@H]3C)Oc4c(C)c(O)c5c6O
InChI InChI=1S/C47H64N4O12/c1-24-13-12-14-25(2)46(59)49-37-32(23-48-51-20-18-50(19-21-51)31-15-10-11-16-31)41(56)34-35(42(37)57)40(55)29(6)44-36(34)45(58)47(8,63-44)61-22-17-33(60-9)26(3)43(62-30(7)52)28(5)39(54)27(4)38(24)53/h12-14,17,22-24,26-28,31,33,38-39,43,53-57H,10-11,15-16,18-21H2,1-9H3,(H,49,59)/b13-12+,22-17+,25-14-,48-23+/t24-,26+,27+,28+,33-,38-,39+,43+,47-/m0/s1^Y Commenting here^[1] Key:WDZCUPBHRAEYDL-GZAUEHORSA-N^Y
^NY (what is this?) (verify)

References

^ Hello world